These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21857299)

  • 1. No need for apologies.
    El-Sadr WM; Gonsalves G; Mugyenyi P
    J Acquir Immune Defic Syndr; 2011 Aug; 57 Suppl 2():S68-71. PubMed ID: 21857299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Game changers: why did the scale-up of HIV treatment work despite weak health systems?
    De Cock KM; El-Sadr WM; Ghebreyesus TA
    J Acquir Immune Defic Syndr; 2011 Aug; 57 Suppl 2():S61-3. PubMed ID: 21857297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging HIV programs to deliver an integrated package of health services: some words of caution.
    Grépin KA
    J Acquir Immune Defic Syndr; 2011 Aug; 57 Suppl 2():S77-9. PubMed ID: 21857301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bridging the divide.
    El-Sadr WM; Rabkin M; Atun R; De Cock KM
    J Acquir Immune Defic Syndr; 2011 Aug; 57 Suppl 2():S59-60. PubMed ID: 21857296
    [No Abstract]   [Full Text] [Related]  

  • 5. Why did the scale-up of HIV treatment work? A case example from Malawi.
    Harries AD; Makombe SD; Libamba E; Schouten EJ
    J Acquir Immune Defic Syndr; 2011 Aug; 57 Suppl 2():S64-7. PubMed ID: 21857298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Building a durable response to HIV/AIDS: implications for health systems.
    Atun R; Bataringaya J
    J Acquir Immune Defic Syndr; 2011 Aug; 57 Suppl 2():S91-5. PubMed ID: 21857305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A one-time-only combination: Emergency medicine exports and the TRIPS agreement under Canada's access to medicines regime.
    Weber A; Mills L
    Health Hum Rights; 2010 Jun; 12(1):109-22. PubMed ID: 20930258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm.
    Moatti JP; N'Doye I; Hammer SM; Hale P; Kazatchkine M
    Nat Med; 2003 Dec; 9(12):1449-52. PubMed ID: 14647513
    [No Abstract]   [Full Text] [Related]  

  • 9. Delivering pediatric HIV care in resource-limited settings: cost considerations in an expanded response.
    Tolle MA; Phelps BR; Desmond C; Sugandhi N; Omeogu C; Jamieson D; Ahmed S; Reuben E; Muhe L; Kellerman SE;
    AIDS; 2013 Nov; 27 Suppl 2():S179-86. PubMed ID: 24361627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical interactions between the Global Fund-supported HIV programs and the health system in Ghana.
    Atun R; Pothapregada SK; Kwansah J; Degbotse D; Lazarus JV
    J Acquir Immune Defic Syndr; 2011 Aug; 57 Suppl 2():S72-6. PubMed ID: 21857300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral load monitoring in resource-limited settings: a medical and public health priority.
    Ford N; Roberts T; Calmy A
    AIDS; 2012 Aug; 26(13):1719-20. PubMed ID: 22874478
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV prevention and treatment in Africa.
    Laurence J
    AIDS Patient Care STDS; 2000 Aug; 14(8):399-400. PubMed ID: 10977967
    [No Abstract]   [Full Text] [Related]  

  • 13. TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges.
    Orsi F; D'Almeida C; Hasenclever L; Camara M; Tigre P; Coriat B
    AIDS; 2007 Oct; 21(15):1997-2003. PubMed ID: 17885289
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV/AIDS. The great funding surge.
    Cohen J
    Science; 2008 Jul; 321(5888):512-9. PubMed ID: 18653876
    [No Abstract]   [Full Text] [Related]  

  • 15. How should access to antiretroviral treatment be measured?
    Johnson LF; Boulle A
    Bull World Health Organ; 2011 Feb; 89(2):157-60. PubMed ID: 21346928
    [No Abstract]   [Full Text] [Related]  

  • 16. Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries.
    Penazzato M; Lewis L; Watkins M; Prabhu V; Pascual F; Auton M; Kreft W; Morin S; Vicari M; Lee J; Jamieson D; Siberry GK
    J Int AIDS Soc; 2018 Feb; 21 Suppl 1(Suppl Suppl 1):. PubMed ID: 29485727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scaling-up the use of generic antiretrovirals in resource-limited countries: generic drugs for health.
    Beck EJ; Passarelli C; Lui I; Guichard AC; Simao M; De Lay P; Loures L
    Antivir Ther; 2014; 19 Suppl 3():117-23. PubMed ID: 25310477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crunch time for funding of universal access to antiretroviral treatment for people with HIV infection.
    Maher D; von Schoen-Angerer T; Cohn J
    Int J Clin Pract; 2011 Aug; 65(8):824-7. PubMed ID: 21762306
    [No Abstract]   [Full Text] [Related]  

  • 19. How can earlier entry of patients into antiretroviral programs in low-income countries be promoted?
    Lawn SD; Wood R
    Clin Infect Dis; 2006 Feb; 42(3):431-2; author reply 432-3. PubMed ID: 16392093
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors impacting the provision of antiretroviral therapy to people living with HIV: the view from Haiti.
    Rouzier V; Farmer PE; Pape JW; Jerome JG; Van Onacker JD; Morose W; Joseph P; Leandre F; Severe P; Barry D; Deschamps MM; Koenig SP
    Antivir Ther; 2014; 19 Suppl 3():91-104. PubMed ID: 25310257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.